Recently, the international authoritative financial media "Nikkei Asia" published an in-depth report on the biotechnology field, focusing on the rapid development of China's biopharmaceutical industry and its similarities to the successful path of the electric vehicle industry.Signet Therapeutics, as a representative of innovative pharmaceutical companies in China, was mentioned and quoted multiple times in the report. The insights of the company's founder and CEO, Dr. Haisheng Zhang, on industry trends were also prominently featured in the article.
Dr. Haisheng Zhang pointed out in the report: "In a sense, China's biotechnology industry is like the electric vehicle industry. Once we establish the supply chain, we can produce products of equal quality.The report analysis pointed out that, after accumulating extensive experience in producing generic drugs and conducting clinical trials for global leading pharmaceutical companies, enterprises in China are now transforming from generic drug suppliers to innovative drug research and development enterprises tackling cancer and rare diseases.
Facing the current fierce industry competition and complex international environment, Dr. Hai Sheng Zhang compared China's biopharmaceuticals industry to the Internet bubble of the past: "Those companies that can survive in this cutthroat competition will eventually become industry leaders.” He believes that as long as the product is excellent enough, there will definitely be diverse channels to reach the market.“In fact, the attention and suppression from the U.S. government precisely indicate that we are doing an excellent job.”
The report also specifically pointed out that SIGNET's core drug under development, SIGX1094R, has received the Fast Track Designation (FTD) from the U.S. FDA and has entered the Phase I clinical trial stage.This milestone means that Signet Therapeutics is poised to enter the world's largest innovative drug market—the U.S. market, which accounts for approximately 45% of global demand for innovative drugs.
Nikkei Asia is an English-language news media outlet under Nikkei Inc., focusing on the Asian market. It is dedicated to providing business, economic, political, and technology news covering Japan and the entire Asian region.
About SIGNET
SIGNET is a global pioneer in the "organoid + AI"-powered innovative targeted drug R&D model, and is a national high-tech enterprise as well as a specialized and innovative enterprise. The company's founding team consists of top talents from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As first/corresponding authors, they have published over 20 groundbreaking research papers on gastric cancer and esophageal cancer in journals with impact factors exceeding 20, such as Nature, Nature Medicine, and Cancer Cell, establishing themselves as global leaders in the field of gastric and esophageal cancer research. Since its establishment in Shenzhen at the end of 2020, the company has completed nearly 220 million yuan in financing and project funding, and holds more than 40 core intellectual properties.
The company currently has four first-in-class drug pipelines and one organoid platform in its portfolio. Its core pipeline, SIGX1094R, is the world’s first targeted drug for diffuse gastric cancer. It has received IND approval from both the U.S. FDA and China's NMPA, as well as Orphan Drug Designation (ODD) and Fast Track Designation (FTD) from the U.S. FDA. In August 2025, this drug was nominated for the Galien Award, known as the "Nobel Prize of the pharmaceutical industry." It is currently undergoing Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world’s first drug to be advanced to the clinical stage through an "organoid + AI" technology platform and is expected to enter Phase II clinical trials by the end of 2025.
Since its establishment at the end of 2020, Signet Therapeutics' forward-looking strategic layout of an "Organoid + AI"-powered technology system for innovative targeted cancer drug development has gained international authoritative recognition. It was featured on the homepage of the globally renowned biotech media Fierce Biotech and hailed as the "NEXT Generation" paradigm for cancer drug research and development. In April 2025, the U.S. FDA officially issued a statement explicitly supporting the gradual replacement of traditional animal experiments with organoid and AI technologies, fully validating the foresight and scientific rigor of the company’s technical layout from four years prior.
1
END
1
